Capecitabine Market By Indication (Colorectal Cancer, Breast Cancer, Others) , By Drug Type (Branded, Generic) By End User (Hospitals, Homecare, Specialty Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

The global capecitabine market was valued at $0.4 billion in 2023, and is projected to reach $0.7 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.

Capecitabine is an oral chemotherapy medication used in the treatment of various cancers, including breast, colon, and rectal cancers. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and spread of cancer cells. Capecitabine is a prodrug, meaning it is converted into its active form, 5-fluorouracil (5-FU), in the body. Once converted, 5-FU inhibits the synthesis of DNA and RNA in cancer cells, leading to their death. Traditional chemotherapy drugs administered intravenously, whereas capecitabine is taken orally, usually in the form of tablets. This offers convenience to patients and allows for outpatient treatment in many cases.

The growth of the capecitabine market is driven by rise in the prevalence of cancer. With the growing number of cancer patients globally, there is surge in demand for the effective treatment option. Moreover, rise in geriatric population has emerged as a significant driver of the capecitabine market. As individuals age, they become more susceptible to developing cancer due to factors such as accumulated genetic mutations, weakened immune systems, and prolonged exposure to carcinogens over their lifetime. This demographic shift toward an aging population has led to a higher prevalence of cancer diagnoses among older adults, creating a greater demand for effective cancer treatments such as capecitabine.

However, adverse effects related to capecitabine, such as anemia, chest discomfort, vomiting, and blood clotting disorders, hamper the growth of the market. On the other hand, product innovation, launches, and diversification present lucrative opportunities for the market players. For instance, in December 2022, Shilpa Medicare Ltd. announced the launch of the Capecitabine 1000 MG dispersible tablet with novel technology of faster dispersion within 90 seconds. The product is supported by required scientific proof and comparative bioequivalence studies and is approved by Central Drugs Standard Control Organisation (CDSCO) -the National Regulatory Authority (NRA) of India, responsible for ensuring the safety, efficacy, and quality of medical products in the country. The product is used for treatment of colorectal and metastatic breast cancer.

Segmentation Overview

The global capecitabine market is segmented into indication, drug type, end user, and region. By indication, the market is divided into colorectal cancer, breast cancer, and others. Depending on drug type, it is categorized into branded and generic. According to end user, the market is classified into hospitals, homecare, specialty centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By indication, the breast cancer segment was the largest shareholder in the market in 2023.

Depending on drug type, the branded segment held the highest market share in 2023.

According to end user, the hospitals segment accounted for the maximum share of the market in 2023.

Region wise, North America dominated the capecitabine market in 2023.

Competitive Scenario

The major players operating in the capecitabine market include F. Hoffmann-La Roche Ltd., Mylan N.V, Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., Dr. Reddy's Laboratories Ltd., Novartis AG, Bayer AG, Eli Lilly and Company, and Merck & Co., Inc. Other players in the market include GlaxoSmithKline Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin, and Alkem Labs Ltd. These players have adopted several strategies, including product diversification & innovation, mergers & acquisitions, and collaborations to maintain their foothold in the market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Indication

Colorectal Cancer
Breast Cancer
Others

By Drug Type

Branded
Generic

By End User

Hospitals
Homecare
Specialty Clinics
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Pfizer Inc.
Dr. Reddy's Laboratories Ltd.
Novartis AG
Bayer AG
Eli Lilly and Company.
Merck & Co., Inc.

Product Code: A03017

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: CAPECITABINE MARKET, BY INDICATION

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Indication
4.2. Colorectal Cancer
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Breast Cancer
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Others
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country

CHAPTER 5: CAPECITABINE MARKET, BY DRUG TYPE

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Drug Type
5.2. Branded
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Generic
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country

CHAPTER 6: CAPECITABINE MARKET, BY END USER

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By End User
6.2. Hospitals
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Homecare
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
6.4. Specialty Clinics
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
6.5. Others
- 6.5.1. Key Market Trends, Growth Factors and Opportunities
- 6.5.2. Market Size and Forecast, By Region
- 6.5.3. Market Share Analysis, By Country

CHAPTER 7: CAPECITABINE MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Indication
- 7.2.3. Market Size and Forecast, By Drug Type
- 7.2.4. Market Size and Forecast, By End User
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Capecitabine Market
  - 7.2.6.1. Market Size and Forecast, By Indication
  - 7.2.6.2. Market Size and Forecast, By Drug Type
  - 7.2.6.3. Market Size and Forecast, By End User
- 7.2.7. Canada Capecitabine Market
  - 7.2.7.1. Market Size and Forecast, By Indication
  - 7.2.7.2. Market Size and Forecast, By Drug Type
  - 7.2.7.3. Market Size and Forecast, By End User
- 7.2.8. Mexico Capecitabine Market
  - 7.2.8.1. Market Size and Forecast, By Indication
  - 7.2.8.2. Market Size and Forecast, By Drug Type
  - 7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Indication
- 7.3.3. Market Size and Forecast, By Drug Type
- 7.3.4. Market Size and Forecast, By End User
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Capecitabine Market
  - 7.3.6.1. Market Size and Forecast, By Indication
  - 7.3.6.2. Market Size and Forecast, By Drug Type
  - 7.3.6.3. Market Size and Forecast, By End User
- 7.3.7. France Capecitabine Market
  - 7.3.7.1. Market Size and Forecast, By Indication
  - 7.3.7.2. Market Size and Forecast, By Drug Type
  - 7.3.7.3. Market Size and Forecast, By End User
- 7.3.8. UK Capecitabine Market
  - 7.3.8.1. Market Size and Forecast, By Indication
  - 7.3.8.2. Market Size and Forecast, By Drug Type
  - 7.3.8.3. Market Size and Forecast, By End User
- 7.3.9. Italy Capecitabine Market
  - 7.3.9.1. Market Size and Forecast, By Indication
  - 7.3.9.2. Market Size and Forecast, By Drug Type
  - 7.3.9.3. Market Size and Forecast, By End User
- 7.3.10. Spain Capecitabine Market
  - 7.3.10.1. Market Size and Forecast, By Indication
  - 7.3.10.2. Market Size and Forecast, By Drug Type
  - 7.3.10.3. Market Size and Forecast, By End User
- 7.3.11. Rest of Europe Capecitabine Market
  - 7.3.11.1. Market Size and Forecast, By Indication
  - 7.3.11.2. Market Size and Forecast, By Drug Type
  - 7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Indication
- 7.4.3. Market Size and Forecast, By Drug Type
- 7.4.4. Market Size and Forecast, By End User
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Capecitabine Market
  - 7.4.6.1. Market Size and Forecast, By Indication
  - 7.4.6.2. Market Size and Forecast, By Drug Type
  - 7.4.6.3. Market Size and Forecast, By End User
- 7.4.7. China Capecitabine Market
  - 7.4.7.1. Market Size and Forecast, By Indication
  - 7.4.7.2. Market Size and Forecast, By Drug Type
  - 7.4.7.3. Market Size and Forecast, By End User
- 7.4.8. Australia Capecitabine Market
  - 7.4.8.1. Market Size and Forecast, By Indication
  - 7.4.8.2. Market Size and Forecast, By Drug Type
  - 7.4.8.3. Market Size and Forecast, By End User
- 7.4.9. India Capecitabine Market
  - 7.4.9.1. Market Size and Forecast, By Indication
  - 7.4.9.2. Market Size and Forecast, By Drug Type
  - 7.4.9.3. Market Size and Forecast, By End User
- 7.4.10. South Korea Capecitabine Market
  - 7.4.10.1. Market Size and Forecast, By Indication
  - 7.4.10.2. Market Size and Forecast, By Drug Type
  - 7.4.10.3. Market Size and Forecast, By End User
- 7.4.11. Rest of Asia-Pacific Capecitabine Market
  - 7.4.11.1. Market Size and Forecast, By Indication
  - 7.4.11.2. Market Size and Forecast, By Drug Type
  - 7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Indication
- 7.5.3. Market Size and Forecast, By Drug Type
- 7.5.4. Market Size and Forecast, By End User
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Capecitabine Market
  - 7.5.6.1. Market Size and Forecast, By Indication
  - 7.5.6.2. Market Size and Forecast, By Drug Type
  - 7.5.6.3. Market Size and Forecast, By End User
- 7.5.7. Saudi Arabia Capecitabine Market
  - 7.5.7.1. Market Size and Forecast, By Indication
  - 7.5.7.2. Market Size and Forecast, By Drug Type
  - 7.5.7.3. Market Size and Forecast, By End User
- 7.5.8. South Africa Capecitabine Market
  - 7.5.8.1. Market Size and Forecast, By Indication
  - 7.5.8.2. Market Size and Forecast, By Drug Type
  - 7.5.8.3. Market Size and Forecast, By End User
- 7.5.9. Rest of LAMEA Capecitabine Market
  - 7.5.9.1. Market Size and Forecast, By Indication
  - 7.5.9.2. Market Size and Forecast, By Drug Type
  - 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. F. Hoffmann-La Roche Ltd.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. Mylan N.V.
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. Teva Pharmaceutical Industries Ltd.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. Sanofi
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. Pfizer Inc.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. Dr. Reddy's Laboratories Ltd.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. Novartis AG
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. Bayer AG
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. Eli Lilly And Company.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. Merck And Co., Inc.
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments